Evidence map›Paper›PMID 35321639›Full record

ArticleJournal of neurodevelopmental disorders2022

Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome.

Jessica Famula, Emilio Ferrer, Randi J Hagerman, Flora Tassone, Andrea Schneider, Susan M Rivera, David Hessl

Open access · goldAbstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Health Effects of Sleep Quality in Premutation Carrier Mothers of Individuals With Fragile X Syndrome.American journal on intellectual and developmental disabilities · 2023
    Article
  10. Article
  11. Sensorimotor and inhibitory control in agingFrontiers in human neuroscience · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jessica FamulaMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, 95817, USA.
Emilio FerrerDepartment of Psychology, University of California Davis, Davis, CA, USA.
Randi J HagermanMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, 95817, USA.
Flora TassoneMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, 95817, USA.
Andrea SchneiderMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, 95817, USA.
Susan M RiveraMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, 95817, USA.
David HesslMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, 95817, USA. drhessl@ucdavis.edu.ORCID 0000-0002-3460-9805
University of California, Davis · USUniversity of California System · US

Funding

Restoring FMRP Phenotypes Frpm Temporal Regional and Splice- Isoforms VarationsP30HD002274 · NICHD · UNIVERSITY OF WASHINGTON · PI GURALNICK, MICHAEL J · 1985 to 2013
$33.6M
GENOTYPE/PHENOTYPE RELATIONSHIPS IN FRAGILE X FAMILIESR01HD036071 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI PAUL J HAGERMAN, RANDI J. HAGERMAN · 1998 to 2026
$13.8M
Research Project: Pathologic Significance of Maternal AutoantibodiesP50HD103526 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEONARD J. ABBEDUTO, Melissa Dawn Bauman · 2020 to 2026
$9.7M
Characterization and Treatment of CNS Abnormalities in Premutation Carriers (4 ofRL1AG032115 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, RANDI J. · 2007 to 2011
$5.8M
Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01MH078041 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HESSL, DAVID R, RIVERA, SUSAN M · 2007 to 2017
$5.4M
Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01NS110100 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAVID R HESSL, Susan M Rivera · 2018 to 2026
$5.4M
NIA NIH HHS RL1 AG032115NICHD NIH HHS P30 HD002274NICHD NIH HHS P50 HD103526NICHD NIH HHS R01 HD036071NIMH NIH HHS R01 MH078041NINDS NIH HHS R01 NS110100
6 · The paper itself

Abstract

backgroundCarriers of the FMR1 premutation are at increased risk of developing a late-onset progressive neurodegenerative disease, fragile X-associated tremor/ataxia syndrome (FXTAS), characterized by intention tremor, gait ataxia, and cognitive decline. Cross-sectional studies to date have provided evidence that neuropsychological changes, such as executive function alterations, or subtle motor changes, may precede the onset of formal FXTAS, perhaps characterizing a prodromal state. However, the lack of longitudinal data has prevented the field from forming a clear picture of progression over time within individuals, and we lack consensus regarding early markers of risk and measures that may be used to track response to intervention.

methodsThis was a longitudinal study of 64 male FMR1 premutation carriers (Pm) without FXTAS at study entry and 30 normal controls (Nc), aged 40 to 80 years (Pm M = 60.0 years; Nc M = 57.4 years). Fifty of the Pm and 22 of the Nc were re-assessed after an average of 2.33 years, and 37 Pm and 20 Nc were re-assessed a third time after an average of another 2.15 years. Eighteen of 64 carriers (28%) converted to FXTAS during the study to date. Neuropsychological assessments at each time point, including components of the Cambridge Neuropsychological Test Automated Battery (CANTAB), tapped domains of episodic and working memory, inhibitory control, visual attention, planning, executive control of movement, and manual speed and dexterity. Age-based mixed models were used to examine group differences in change over time on the outcomes in the full sample, and differences were further evaluated in 15 trios (n = 45; 15 Pm "converters," 15 Pm "nonconverters," 15 Nc) that were one-one matched on age, education, and socioeconomic status.

resultsCompared to Nc, Pm showed significantly greater rates of change over time in visual working memory, motor dexterity, inhibitory control, and manual movement speed. After multiple comparison correction, significant effects remained for motor dexterity. Worsening inhibitory control and slower manual movements were related to progression in FXTAS stage, but these effects became statistically non-significant after correcting for multiple comparisons. Higher FMR1 mRNA correlated with worsening manual reaction time but did not survive multiple comparisons and no other molecular measures correlated with neuropsychological changes. Finally, trio comparisons revealed greater rate of decline in planning and manual movement speed in Pm converters compared to Pm nonconverters.

conclusionsAccelerated decline in executive function and subtle motor changes, likely mediated by frontocerebellar circuits, may precede, and then track with the emergence of formal FXTAS symptoms. Further research to develop and harmonize clinical assessment of FMR1 carriers across centers is needed to prepare for future prophylactic and treatment trials for this disorder.

Indexed as

Neurodegenerative DiseasesTremorAdultAgedAged, 80 and overAtaxiaCross-Sectional StudiesFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansLongitudinal StudiesMaleMemory, Short-TermMiddle AgedFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1AtaxiaCANTABExecutive functionFragile X premutationFXTASTremor

Identifiers

PMID35321639
PMCPMC8942145
OpenAlexW4221016088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.